Itraconazole, 100 mg capsules 14 pcs

Vulvovaginal candidiasis;

Active ingredient

Composition

How to take, the dosage

Internal. Immediately after a meal. Capsules are swallowed whole.

The elimination of the drug itraconazole from skin and nail tissue is slower than that from plasma. Thus, optimal clinical and mycological effects are achieved 2-4 weeks after the end of treatment for skin infections and 6-9 months after the end of treatment for nail infections.

The duration of treatment can be adjusted depending on the clinical picture of the treatment:

Interaction

Examples of such medications are:

Drugs that should not be prescribed at the same time as itraconazole:

Special Instructions

Women of childbearing age taking Itraconazole should use reliable methods of contraception throughout the course of treatment until their first menstrual period after completion of treatment.

Itraconazole has been found to have a negative inotropic effect. Caution should be exercised when concomitant administration of itraconazole and calcium channel blockers, which may have the same effect. There have been reported cases of chronic heart failure associated with taking Itraconazole.

Itraconazole should not be taken in patients with chronic heart failure or with the presence of this disease in the history, except in cases when the possible benefit significantly exceeds the potential risk. Factors such as severity of indications, dosing regimen, and individual risk factors for chronic heart failure should be taken into consideration when evaluating the benefit-risk ratio on an individual basis.

Risk factors include the presence of heart disease, such as coronary heart disease or valve lesions; serious lung disease, such as obstructive lung disease; and renal failure or other conditions accompanied by edema. Such patients should be informed about the signs and symptoms of congestive heart failure. Treatment should be performed with caution, and the patient should be monitored for signs of congestive heart failure. If they appear, Itraconazole should be discontinued.

In reduced gastric acidity: in this condition, absorption of Itraconazole from the capsules is impaired. Patients taking antacids (e.g., aluminum hydroxide) should use them not earlier than 2 hours after taking Itraconazole capsules. In patients with achlorhydria or who use H2-histamine receptor blockers and proton pump inhibitors, it is recommended to take Itraconazole capsules with drinks containing cola.

In very rare cases during the use of Itraconazole severe toxic liver damage developed, including cases of acute hepatic failure with fatal outcome. In most cases this was observed in patients who already had liver disease, in patients with other severe diseases who received itraconazole therapy for systemic indications, as well as in patients who received other medicinal products with hepatotoxic effect.

In some patients there were no obvious risk factors for liver damage. Several such cases occurred in the first month of therapy, and some occurred in the first week of treatment. In this regard, it is recommended to monitor regularly the liver function in patients receiving itraconazole therapy. Patients should be warned to contact their physician immediately in case of symptoms suggestive of hepatitis, namely: anorexia, nausea, vomiting, weakness, abdominal pain and darkened urine.

In case of appearance of these symptoms it is necessary to stop therapy immediately and conduct liver function tests. Patients with elevated concentration of “liver” enzymes or liver disease in active phase, or in patients with past toxic liver damage while taking other drugs should not be administered treatment with Itraconazole unless the expected benefits justify the risk of liver damage. In these cases it is necessary to monitor the concentration of “liver” enzymes during treatment.

Hepatic disorders: Itraconazole is metabolized mainly in the liver. As the total half-life of itraconazole is slightly prolonged in patients with hepatic impairment, it is recommended to monitor the concentration of itraconazole in plasma and adjust the dose of the drug, if necessary.

Renal disorders: Since in patients with renal impairment the total half-life of itraconazole is slightly prolonged, it is recommended to monitor the plasma concentration of itraconazole and adjust the dose of the drug, if necessary.

Patients with immunodeficiencies: bioavailability of itraconazole in per oral administration may be reduced in some patients with impaired immunity, such as patients with neutropenia, patients with AIDS or patients who underwent surgery for organ transplantation.

Patients with systemic fungal infections that are life-threatening: Due to the pharmacokinetic characteristics, Itraconazole in capsule form is not recommended for initiating treatment of systemic mycoses that are life-threatening in patients.

AIDS patients.

The treating physician should evaluate the need for maintenance therapy in AIDS patients previously treated for systemic fungal infections such as sporotrichosis, blastomycosis, histoplasmosis, or cryptococcosis (both meningeal and nonmeningeal) who are at risk for relapse.

The clinical data on the use of Itraconazole capsules in pediatric practice are limited. Itraconazole capsules should not be administered to children unless the expected benefit exceeds the possible risk.

The treatment should be stopped if peripheral neuropathy occurs, which may be associated with the intake of Itraconazole capsules.

There are no data on cross-sensitivity to itraconazole and other azole antifungal drugs.

Effects on ability to drive and operate machinery

Itraconazole may cause dizziness and other side effects that may affect ability to drive vehicles and other machinery that require extra attention at work.

Contraindications

Side effects

Similarities